You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
TaurusNXT® NON-GLUTARALDEHYDE CROSSLINKED DRY-TISSUE TAVR SYSTEM COMPLETED ALL PATIENT ENROLLMENT OF ITS PIVOTAL CLINICAL TRIAL
2024-03-01 09:40:40

In February 2024, TaurusNXT® Non-glutaraldehyde Crosslinked dry-tissue TAVR system, a thirdgeneration TAVR system internally developed to address the challenges of valve durability, completed all patient enrollment of its pivotal clinical trial. The design of TaurusNXT® is significantly different from TaurusOne® and TaurusElite®. TaurusNXT® uniquely adopts non-glutaraldehyde bio-tissue crosslinking technology for leaflet treatment, which eliminates the root cause of valve calcification, thus solving the problem of prosthetic valve degeneration.


Top